Cellebrite DI Ltd. Q2 2026 Earnings Call Summary
Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.
How this was made
The 30-second read
Why it matters
The key tradable update is the guidance reset: full-year ARR lowered due to moderated Insights conversion pricing and removed upside from complex government deals, while adjusted EBITDA target increased on operational efficiency and headcount discipline. Deal slippage is attributed to procurement complexities and administrative hurdles, not lost competitive share.
Market read
Traders should focus on the ARR guidance cut versus the raised adjusted EBITDA target, plus the stated drivers of deal delays and pricing uplift shortfall, which can drive near-term estimate revisions.
What to watch
Genesis consumption-based launch could re-rate the revenue mix over time, and the company’s claim of no competitor wins may reduce competitive fear despite weaker pricing uplift.
Background
Cellebrite is transitioning from a digital forensics tool provider toward a cloud-native investigative intelligence platform with an AI layer, while navigating foreign entity status requirements and new EU data sovereignty rules.
Ticker impact
Cellebrite lowered full-year ARR guidance to $550M-$560M and raised adjusted EBITDA to $153M-$159M amid delayed government deals and weaker Insights pricing uplift.
Choppy to downside bias on ARR-miss optics, with partial support from higher EBITDA target and FedRAMP High moat commentary.
The article’s newest decision-grade facts are the revised ARR and EBITDA targets plus explanations for deal slippage, procurement barriers, and pricing uplift; these typically drive near-term multiple and estimate revisions.
Market effects
Digital forensics and investigative intelligence vendors may face longer cloud procurement cycles and higher administrative friction for government contracting.
EU cloud transitions face additional legal review delays in Germany and the U.K., potentially affecting regional deal conversion timelines.
FedRAMP High positioning remains a key differentiator for US federal digital forensics providers, influencing competitive dynamics for cloud-based contracts.
Counterpoint
The ARR guide cut may be largely timing-related (about 6-week delays) rather than demand destruction, so forward estimates could stabilize if procurement hurdles clear.
Key entities
- companyCellebrite DI Ltd.
Digital forensics and investigative intelligence platform provider issuing revised ARR and adjusted EBITDA guidance and discussing platform transition, procurement barriers, and product launches.
- personShiv Ramji
Appointed CEO to accelerate the transition to a product-centric, cloud-native architecture.
- productCorellium
Product whose growth expectations were moderated to 1 to 2 percentage points.
- productGenesis
Consumption-based product launched with early ARR traction and a new revenue dynamic for in-cycle upgrades.
